A follow-on Study to Assess Long-term Safety and Tolerability of i.c.v Administration of sNN0029 in Patients With ALS
Status:
Terminated
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
This is an open-label, follow-on phase 1 study to assess the long-term safety and
tolerability of continuous i.c.v administration of 4 μg sNN0029/day in patients with ALS who
previously participated in study sNN0029-003